StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/302% above fair value
$64.63−1.20 (-1.82%)

Close on Nov 20, 2026Market cap $15.77BP/E 19.4Yield –

Exelixis gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Exelixis's gross profit for the twelve months ending Oct 2, 2026 was $2.40B, up 8.7% year over year. For fiscal 2025 it was $2.24B, up 6.9% from the year before. Over ten years it grew 52.3% a year on average. The highest annual figure on record is $2.24B in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Jan 2, 2026$2.24B+6.9%
FY2024Jan 3, 2025$2.09B+19.0%
FY2023Dec 29, 2023$1.76B+13.2%
FY2022Dec 30, 2022$1.55B+12.4%
FY2021Dec 31, 2021$1.38B+45.3%
FY2020Jan 1, 2021$951.27M+1.8%
FY2019Jan 3, 2020$934.68M+13.0%
FY2018Dec 28, 2018$827.48M+89.2%
FY2017Dec 29, 2017$437.41M+136.6%
FY2016Dec 31, 2016$184.90M+455.6%
FY2015Dec 31, 2015$33.28M+44.3%
FY2014Dec 31, 2014$23.07M-23.7%
FY2013Dec 31, 2013$30.22M-36.3%
FY2012Dec 31, 2012$47.45M-83.6%
FY2011Dec 31, 2011$289.64M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$632.46M+9.2%
Q2 FY2026Jul 3, 2026$608.03M+10.8%
Q1 FY2026Apr 3, 2026$590.86M+10.2%
Q4 FY2025Jan 2, 2026$572.18M+4.6%
Q3 FY2025Oct 3, 2025$579.18M+10.9%
Q2 FY2025Jul 4, 2025$548.79M-11.4%
Q1 FY2025Apr 4, 2025$536.28M+32.8%
Q4 FY2024Jan 3, 2025$546.79M+19.4%
Q3 FY2024Sep 27, 2024$522.21M+15.2%
Q2 FY2024Jun 28, 2024$619.51M+37.0%
Q1 FY2024Mar 29, 2024$403.97M+2.4%
Q4 FY2023Dec 29, 2023$457.90M+12.2%
Q3 FY2023Sep 29, 2023$453.15M+14.3%
Q2 FY2023Jun 30, 2023$452.14M+11.4%
Q1 FY2023Mar 31, 2023$394.47M+15.1%
Q4 FY2022Dec 30, 2022$408.00M-6.9%
Q3 FY2022Sep 30, 2022$396.43M+25.2%
Q2 FY2022Jul 1, 2022$405.95M+9.6%
Q1 FY2022Apr 1, 2022$342.78M+33.4%
Q4 FY2021Dec 31, 2021$438.22M+129.1%
Q3 FY2021Oct 1, 2021$316.55M+98.0%
Q2 FY2021Jul 2, 2021$370.29M+118.5%
Q1 FY2021Apr 2, 2021$257.03M+39.2%
Q4 FY2020Jan 1, 2021$191.32M+3.7%
Q3 FY2020Oct 2, 2020$159.86M-13.2%
Q2 FY2020Jul 3, 2020$169.51M-8.9%
Q1 FY2020Apr 3, 2020$184.59M+7.3%
Q4 FY2019Jan 3, 2020$184.41M+9.2%
Q3 FY2019Sep 27, 2019$184.23M+18.4%
Q2 FY2019Jun 28, 2019$186.14M+33.1%
Q1 FY2019Mar 29, 2019$172.08M+33.8%
Q4 FY2018Dec 28, 2018$168.87M+84.5%
Q3 FY2018Sep 28, 2018$155.59M+69.6%
Q2 FY2018Jun 29, 2018$139.84M+64.5%
Q1 FY2018Mar 30, 2018$128.63M+95.9%
Q4 FY2017Dec 29, 2017$91.52M+82.8%
Q3 FY2017Sep 30, 2017$91.76M–
Q2 FY2017Jun 30, 2017$84.99M–
Q1 FY2017Mar 31, 2017$65.67M–
Q4 FY2016Dec 31, 2016$50.06M–

More Exelixis figures

See a number that looks wrong?